ERBB2 and breast cancer: In the clinic, neratinib extends OS of patients with early- and late-stage HER2-positive breast cancer and is approved by the United States Food and Drug Administration for use as monotherapy in adjuvant breast cancer following 1 year of trastuzumab, and in combination with capecitabine in third-line metastatic breast cancer23,24.